TOSEDOSTAT PLUS LOW DOSE CYTARABINE COMBO INDUCES A HIGH RATE OF RESPONSES THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML: FINAL RESULTS OF A PHASE II MULTICENTER STUDY

被引：0

作者：

Visani, G. ^{[1
]}

Loscocco, F. ^{[1
]}

Fuligni, F. ^{[2
]}

Zuffa, E. ^{[3
]}

Sensi, A. ^{[4
]}

Zaccaria, A. ^{[3
]}

Musuraca, G. ^{[5
]}

Giannini, B. ^{[4
]}

Lucchesi, A. ^{[5
]}

Fabbri, F. ^{[5
]}

Mianulli, A. M. ^{[6
]}

Tosi, P. ^{[6
]}

Tonelli, M. ^{[4
]}

Candoni, A. ^{[7
]}

Fanin, R. ^{[7
]}

Sparaventi, G. ^{[1
]}

Gobbi, M. ^{[8
]}

Clavio, M. ^{[8
]}

Rocchi, M. ^{[9
]}

Piccaluga, P. ^{[2
]}

Isidori, A. ^{[1
]}

机构：

[1] Hematol & Stem Cell Transplant Ctr, AORMN, Pesaro, Italy

[2] Univ Bologna, S Orsola M Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Hematopatol Sect, Bologna, Italy

[3] Ravenna Hosp, Hematol, Ravenna, Italy

[4] Ctr Serv Lab Unico AVR, Genet Med, Pievesestina Di Cesana, Italy

[5] IRST Meldola, Oncohematol, Meldola, Italy

[6] Rimini Hosp, Hematol, Rimini, Italy

[7] Azienda Osped Univ S Maria Misericordia, Ctr Trapianti & Terapie Cellulari Carlo Melzi DIS, Clin Ematol, Udine, Italy

[8] Univ Genoa, Hematol, Genoa, Italy

[9] Univ Urbino, Inst Biomath, I-61029 Urbino, Italy

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P564

引用

页码：215 / 215

页数：1

共 44 条

[41] Final Results of a Phase II Danish Trial Testing Low Dose Total Body Irradiation Following Six Bi-Weekly RCHOP-14 Plus 2 Extra Rituximab in Elderly High risk Patients with Aggressive CD20+Diffuse Large B-Cell Lymphoma (DLBCL).
Safwat, Akmal
Specht, Lena
Hansen, Flemming
Hansen, Mads
Jurlander, Jesper
d'Amore, Francesco
BLOOD, 2008, 112 (11) : 372 - 373
[42] Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
H Zwierzina
S Suciu
J Loeffler-Ragg
R Neuwirtova
P Fenaux
M Beksac
J Harousseau
V Nuessler
J Cermak
G Solbu
R Willemze
T de Witte
S Amadori
Leukemia, 2005, 19 : 1929 - 1933
[43] Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia:: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
Zwierzina, H
Suciu, S
Loeffler-Ragg, J
Neuwirtova, R
Fenaux, P
Beksac, M
Harousseau, J
Nuessler, V
Cermak, J
Solbu, G
Willemze, R
de Witte, T
Amadori, S
LEUKEMIA, 2005, 19 (11) : 1929 - 1933
[44] High CR rate and prolonged EFS in aaIPI 2-3 diffuse large B-cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen):: Results of a prospective phase II multicenter study sponsored by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
Tarella, C
Zanni, M
Di Nicola, M
Patti, C
Castellino, C
Pescarollo, A
Zoli, V
Caracciolo, D
Ladetto, M
Magni, M
Devizzi, L
Boccadoro, M
Bregni, M
Corradini, P
Gallamini, A
Majolino, I
Mirto, S
Gianni, AM
BLOOD, 2005, 106 (11) : 585A - 585A

← 1 2 3 4 5 →